← Back to Fundingfunding

Neurotech funding hits $2.64 billion in H1 2026 — a landscape view

Neurotechnology companies raised approximately $2.64 billion in H1 2026, a 31% increase over H1 2025. Key raises include Setpoint Medical ($115M), Nervonik ($52.5M), Aneuvo ($22M), and Aurenar ($5.7M).

Body Mind StateAugust 17, 20266 min read
Neurotech funding hits $2.64 billion in H1 2026 — a landscape view

Overview

Neurotechnology companies raised approximately $2.64 billion in disclosed funding during the first half of 2026, a 31% increase over the same period in 2025 ($2.01 billion, Pitchbook/NeuroTech Reports).

What's driving the surge

Three converging forces are accelerating capital into neurotechnology: clinical validation milestones, regulatory pathway clarity, and the entry of strategic acquirers.

Key Raises H1 2026

| Company | Round | Amount | Focus | |---|---|---|---| | Setpoint Medical | Series D | $115M | VNS for rheumatoid arthritis | | Nervonik | Series B | $52.5M | Closed-loop PNS for chronic pain | | Aneuvo | Series C | $22M | ECAP-sensing spinal cord stimulation | | Aurenar | Seed | $5.7M | taVNS for ICU inflammation |

What to watch

  • Closed-loop neuromodulation maturing from research concept to commercial reality
  • FDA increasingly comfortable with bioelectronic approaches
  • Strategic acquirers actively participating in early rounds

Related

Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA
funding

Aneuvo raises $22M Series C for ECAP-sensing spinal cord stimulation — ExaStim heads to FDA

Aneuvo closed a $22 million Series C in March 2026 for ExaStim, an ECAP-sensing spinal cord stimulation system for chronic pain. FDA 510(k) submitted May 2026.

Aug 17, 20265 min read
Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation
funding

Aurenar raises $5.7M seed to bring vagus nerve stimulation into the ICU for inflammation

Aurenar closed an oversubscribed $5.7 million seed round in July 2026 to advance V-Link, a non-invasive taVNS device for ICU inflammation. FDA Breakthrough Device designation granted June 2026.

Aug 17, 20264 min read
Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain
funding

Nervonik closes $52.5M Series B for closed-loop peripheral nerve stimulation for chronic pain

Nervonik closed an oversubscribed $52.5 million Series B in April 2026 for its miniaturized, wireless, closed-loop peripheral nerve stimulation platform for chronic neuropathic pain.

Aug 17, 20264 min read

Stay Regulated

Regulate your nervous system from the inside out.

New research, honest product reviews, neurotech funding rounds, and events — delivered weekly, with zero sponsors or ads.